Evidence map›Paper›PMID 42625957›Full record

ArticleMedComm2026

Safety and Efficacy of Vedolizumab for the Patients With Gastrointestinal Acute Graft-Versus-Host Disease Refractory to Steroid Treatment After Allogeneic Hematopoietic Stem Cell Transplantation: A Real-World, Retrospective Multicenter Study (VAST Study).

Leqing Cao, Yi Xia, Song Xue, Jianping Zhang, Jiameng Li, Yuewen Wang, Qi Wen, Ze Tian, Jun Kong, Daoxing Deng and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Leqing CaoPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies Peking University Beijing China.
Yi XiaPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies Peking University Beijing China.
Song XueBeijing Lu Daopei Hospital Beijing China.
Jianping ZhangHebei Yanda Ludaopei Hospital Langfang Hebei Province China.
Jiameng LiPeking University Health Science Center Peking University Beijing China.
Yuewen WangPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies Peking University Beijing China.
Qi WenPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies Peking University Beijing China.
Ze TianPeking University Health Science Center Peking University Beijing China.
Jun KongPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies Peking University Beijing China.
Daoxing DengPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies Peking University Beijing China.
Xiaohui ZhangPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies Peking University Beijing China.
Yang CaoDepartment of Hematology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China.
Na XuDepartment of Hematology Nanfang Hospital Southern Medical University Guangzhou China.
Xiaodong MoPeking University People's Hospital Peking University Institute of Hematology National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies Peking University Beijing China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Steroid-refractory (SR) gastrointestinal (GI) acute graft-versus-host disease (aGVHD) is the major cause of early mortality after allogeneic hematopoietic stem cell transplantation. Vedolizumab could be used as the second- or third-line treatment of GI-aGVHD. Our real-world, retrospective multicenter study, in which 100 SR-GI-aGVHD patients who received vedolizumab were enrolled, confirmed its effectiveness. Note that 411 SR-GI-aGVHD patients who received the best available treatments (BATs) during the same period were enrolled as controls. Inverse probability of treatment weighting (IPTW) and propensity score matching (PSM) were conducted as sensitivity analyses. The overall response rates (ORRs) for SR-GI-aGVHD on day 28 and at any time point were 68.0% and 81.0%, respectively, and the 2-year probabilities of overall survival and nonrelapse mortality were 58.3% and 31.9%, respectively, after vedolizumab treatment. Multivariate analysis revealed that initiating vedolizumab treatment within 7 days after SR-aGVHD onset could help improve the ORR. In the sensitivity analysis, compared with the BATs, vedolizumab improved the ORR and complete response rate, particularly in the stage 3-4 SR-GI-aGVHD subgroup, and it reduced the infection rate after IPTW and PSM adjustment. These findings confirmed the efficacy of vedolizumab in a real-world setting, which can help to control SR-GI-aGVHD more effectively and safely.

Indexed as

acute graft‐versus‐host diseaseallogeneic hematopoietic stem cell transplantationgastrointestinalsteroid refractoryvedolizumab

Identifiers

PMID42625957
PMCPMC13490922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.